These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15083966)

  • 1. [Treatment with high dose of intravenous iron increases mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Martín Reyes G; Valera A; Toledo R
    Nefrologia; 2004; 24(1):87-8. PubMed ID: 15083966
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment with high-dose intravenous iron increases mortality and hospitalization in hemodialysis. The basic idea is more important than the style].
    Fernández-Gallego J
    Nefrologia; 2005; 25(3):340. PubMed ID: 16053019
    [No Abstract]   [Full Text] [Related]  

  • 3. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron supplementation in renal anemia.
    Fishbane S
    Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of IV iron in the treatment of anaemia of ESRD patients on maintenance haemodialysis: an historical and personal view.
    Shaldon S
    Nephrol Dial Transplant; 2007 Jan; 22(1):23-5. PubMed ID: 17088269
    [No Abstract]   [Full Text] [Related]  

  • 6. Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection.
    Ishida JH; Marafino BJ; McCulloch CE; Dalrymple LS; Dudley RA; Grimes BA; Johansen KL
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1799-805. PubMed ID: 26416943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia management and mortality risk in incident hemodialysis patients.
    Auerbach M
    JAMA; 2010 Jul; 304(1):41-2; author reply 42-3. PubMed ID: 20606145
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation.
    Vaziri ND
    Am J Med; 2012 Oct; 125(10):951-2. PubMed ID: 22795817
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin.
    Gallieni M
    Int J Artif Organs; 1998 Nov; 21(11):681-6. PubMed ID: 9894741
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous iron: the iatrogenic kick to lose control over oxygen?
    Deicher R; Hörl WH
    Kidney Blood Press Res; 2002; 25(5):284-8. PubMed ID: 12435873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?
    Deaver K; Bennington L
    Nephrol Nurs J; 2006; 33(4):430-7; quiz 438. PubMed ID: 17002001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 16. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 17. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

  • 19. Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S1-4. PubMed ID: 19010256
    [No Abstract]   [Full Text] [Related]  

  • 20. [Histidine in the treatment of anemia in patients with chronic renal failure treated by hemodialysis].
    Rutkowski B; Góra E; Barlik J; Manitius J; Jakubowski Z
    Pol Tyg Lek; 1987 Aug; 42(34):1031-4. PubMed ID: 3422836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.